LTIMINDTREE/AFORZA
4.4.2024 12:53:31 CEST | Business Wire | Press release
Aforza, the leading cloud and mobile solution specifically built for the Consumer Products industry that empowers businesses of all sizes to protect margins on every channel, and LTIMindtree (NSE: LTIM, BSE: 540005), a global technology consulting and digital solutions company, today announced a strategic partnership to deliver digital transformation in CRM & TPM across the consumer products industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404866939/en/
The partnership between Aforza and LTIMindtree is set to support the front office operations of Consumer Products manufacturers and distributors. This collaboration aims to empower businesses to grow profitably and safeguard margins through comprehensive omnichannel pricing control. It will enable access to real-time data insights, enhancing planning and decision-making capabilities. Additionally, the partnership promises to boost field productivity throughout the value chain by delivering a world-class user experience. With industry-specific offline mobile apps, professionals can work from anywhere, ensuring flexibility and efficiency. The initiative will also focus on increasing distribution, availability, stock accuracy, and fulfilment rates. Furthermore, it will provide robust measures to manage compliance issues effectively and prevent fraud, ensuring a secure and compliant operational environment.
Nachiket Deshpande, Whole-Time Director & Chief Operating Officer, LTIMindtree said, “We strongly believe in investing in our talent to stay ahead of the curve and to help our customers in the Consumer Goods space. With Aforza’s AI innovations and their digital content execution capabilities, the training for our consultants will add to their domain skills and elevate their advisory and implementation capabilities. We see this partnership grow and create an ecosystem of well trained and skilled individuals who will bring exceptional results to our customer.”
“This strategic partnership marks a pivotal moment in our commitment to empowering Consumer Product companies with cutting-edge digital solutions,” says Ed Butterworth, Chief Commercial Officer & Co-Founder of Aforza. “By combining Aforza's industry-specific expertise and LTIMindtree's digital transformation leadership, we will deliver unparalleled value to our customers, fostering growth, innovation, and sustainable success.”
LTIMindtree has established the Aforza Training Academy, with Aforza’s Customer Success Enablement team, to virtually train and certify a full practice of industry consultants. This is a key enabler to build customer success and trust. Collectively, Aforza and LTIMindtree will focus on key segments within the Consumer Products industry, including Beauty, Consumer Healthcare, Luxury Brands, and Food & Beverage.
About Aforza
Aforza helps Consumer Product companies grow confidently & protect margins in uncertain times through a suite of cloud & mobile apps built for the industry. Aforza connects trade planning and field sales teams together to solve the problems of margin erosion, missed revenue opportunities and ineffective trade spend. The Aforza product works out of the box and can be implemented in weeks. The mobile applications work offline and deliver powerful on-device intelligence across Apple iOS and Android devices. Aforza is built on the Salesforce and Google Cloud Platforms which means we can scale fast and deliver continuous innovation with 3 releases a year. Customer success is Aforza's top priority, and we are proud to be trusted by CPG companies in more than 40 countries; including leading breweries, food & beverage manufacturers, consumer healthcare companies and major distributors. To learn more, please visit www.aforza.com
About LTIMindtree
LTIMindtree is a global technology consulting and digital solutions company that enables enterprises across industries to reimagine business models, accelerate innovation, and maximize growth by harnessing digital technologies. As a digital transformation partner to more than 700 clients, LTIMindtree brings extensive domain and technology expertise to help drive superior competitive differentiation, customer experiences, and business outcomes in a converging world. Powered by 82,000+ talented and entrepreneurial professionals across more than 30 countries, LTIMindtree — a Larsen & Toubro Group company — combines the industry-acclaimed strengths of erstwhile Larsen and Toubro Infotech and Mindtree in solving the most complex business challenges and delivering transformation at scale. For more information, please visit https://www.ltimindtree.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404866939/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom